28
Aug 2026
African Bundibugyo ebolavirus vaccine candidate to be advanced to clinical trials
Leading African biopharmaceutical company Minapharm Group (www.Minapharm.com), headquartered in Egypt with subsidiaries in Berlin, will receive up to US$16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, strengthening efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record affecting the Democratic Republic of the Congo (DRC).